retatrutide diabetes type 1 Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide and Type 1 Diabetes:

John had had a lot of difficulty in getting anybody interested in it at all, recalls Andrew Young, the former VP of research at Amylin Pharmaceuticals

Could lower heart risks by improving blood pressure and glucose control

Neuroprotective effects of GLP-1R agonism GLP-1R agonists improve cerebral blood flow (CBF): By enhancing neurovascular coupling, these drugs ensure that blood flow is properly regulated in response to brain activity, improving overall brain function, particularly in obesity and metabolic disorders

The cost to Medicare of covering obesity drugs under Part D has been estimated at between $25 billion and $35 billion over 10 years, which could have been a driving factor in the reluctance or unwillingness of major Part D plan sponsors to participate in the BALANCE model as it was originally designed